instrucUons): Platelets are important for hemostasis in response to vascular damage. Platelet deficiency or hypores?? ponsiveness results in excessive bleeding, whereas hyperactive platelets form pathological thrombi that can occlude blood vessels and cause myocardial infarction or stroke. It is therefore important to understand the mechanisms underlying platelet activation. Platelet activation at sites of vessel injury depends on cell surface adhesion and signaling receptors. Initial activation of platelets adhered to an injured blood vessel is mediated by the fliycofirotein Vl/Fc receptor x (GPVI/FcRy)-chain complex. Subsequent binding of plasma fibrinogen to the integrin allbpS on the activated platelet surface enables recruitment of additional platelets. Differences in the pathways through which GPVI/FcRy-chain and allbps activate platelets therefore offer opportunities for selective modulation of platelet accumulation at early vs. late stages of thrombus formation Activation of platelets via either GPVI or allbp3 requires participation by the cytosolic adaptor molecule, Src homology 2 (SH2) domain-containing jeukocyte grotein of 76 kDa (SLP-76), which coordinates assembly of a multi-molecular complex that activates a fihosphojipase C (PLC) y isoform. However, the domains of, and binding partners for, SLP-76 that support its recruitment to the membrane in GPVI-stimulated platelets are not utilized in allb/33-stimulated platelets.
Specific Aim 1 of this proposal seeks to determine whether the SH2 domain of SLP-76 and the non-T cell activation linker (NTAL) adaptor protein uniquely support flrllbyff3- mediated platelet activation. In addition, platelets express two isoforms of PLCy (yi and y2) and, whereas PLCy2 deficiency has been found to profoundly affect GPVI-mediated platelet activation, it has only mild effects on platelet activation by allbps.
SPECIFIC AIM 2 seeks to use newly-available conditionally PLCyl- deficient mice to determine whether PLC/I makes a more important contribution to allbyff3- than to GPVI- dependent responses. The proposed studies may therefore identify new signal transduction pathway components (NTAL or PLCyl), or new components of molecules that have long been known to participate in platelet signal transduction (SH2 domain of SLP-76), as novel targets for selective modulation of allbp3- dependent platelet accumulation in growing thrombi. The ultimate goal of clarifying unique components of the allbp3 signaling pathways is to enable fine-tuning of platelet adhesion and activation at sites of vascular injury so as to maximize control of bleeding and minimize thrombus growth.

Public Health Relevance

Platelets circulate in the bloodstream and become activated when they encounter a damaged blood vessel. Activated platelets spread out and bind to one another so as to close up the damaged area and initiate wound healing. Our studies are designed to determine how platelet activation is controlled because excessive bleeding occurs when platelets are not active enough and heart attacks or strokes can occur when platelets are too active.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Bloodcenter of Wisconsin, Inc.
United States
Zip Code
Fahs, Scot A; Hille, Matthew T; Shi, Qizhen et al. (2014) A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123:3706-13
Shi, Qizhen; Kuether, Erin L; Chen, Yingyu et al. (2014) Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. Blood 123:395-403
Kanaji, S; Fahs, S A; Ware, J et al. (2014) Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome. J Thromb Haemost 12:1726-32
Zheng, Yongwei; Wang, Alexander W; Yu, Mei et al. (2014) B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood 123:931-4
Elbatarny, M; Mollah, S; Grabell, J et al. (2014) Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia 20:831-5
Weiler, Hartmut (2014) Inflammation-associated activation of coagulation and immune regulation by the protein C pathway. Thromb Res 133 Suppl 1:S32-4
Brott, David A; Katein, Anne; Thomas, Heath et al. (2014) Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury. Toxicol Pathol 42:672-83
Zheng, Yongwei; Yu, Mei; Podd, Andrew et al. (2013) Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood 121:3484-92
Qi, Xiaopeng; Hong, Jessie; Chaves, Lee et al. (2013) Antagonistic regulation by the transcription factors C/EBP* and MITF specifies basophil and mast cell fates. Immunity 39:97-110
Tourdot, Benjamin E; Brenner, Michelle K; Keough, Kathleen C et al. (2013) Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases: a case study involving PECAM-1. Biochemistry 52:2597-608

Showing the most recent 10 out of 176 publications